Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,182 across all filing types
Latest filing 2021-12-14 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin's Goa Manufacturing Plant Receives EIR from US FDA.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the receipt of the Establishment Inspection Report (EIR) from the US FDA for Lupin Limited's Goa manufacturing facility. It is a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which relates to ongoing regulatory disclosures by listed companies. The document is short (4129 characters) and primarily serves as an announcement of a regulatory event rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the category for general regulatory announcements and compliance disclosures that do not fit other specific categories.
2021-12-14 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Lupin's Goa manufacturing plant received an Establishment Inspection Report (EIR) from the US FDA with a classification of Voluntary Action Indicated (VAI). It contains no financial data, no detailed report, no voting results, no management changes, no earnings data, and no regulatory certifications. The document is short (3507 characters) and serves as a public announcement of a regulatory inspection outcome. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories like Annual Report, Earnings Release, or Legal Proceedings.
2021-12-14 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document is a compliance certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015, related to the issuance of duplicate share certificates in lieu of lost certificates. It is addressed to the National Stock Exchange of India and contains details of duplicate share certificates issued. The document is short (1457 characters) and is a regulatory compliance communication rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2021-12-10 English
Intimation regarding issuance of duplicate share certificate to the shareholder in lieu of lost share certificate.
Transaction in Own Shares Classification · 90% confidence The document is an intimation under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015, regarding the issuance of a duplicate share certificate in lieu of a lost share certificate. It includes details of the shareholder, folio number, old and new certificate numbers, and number of shares. This is a notification about a specific share certificate transaction by a company director or related party, which fits the category of Director's Dealing or insider share transactions. However, since it is about issuance of duplicate share certificates due to loss, it is more aligned with a Transaction in Own Shares (POS) rather than a director's personal share transaction. The document is short and specific to share certificate replacement, not a general share issue or capital change. Given the options, the closest and most appropriate classification is Transaction in Own Shares (POS).
2021-12-10 English
Intimation regarding issuance of duplicate share certificate to the shareholder in lieu of lost share certificate.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (BSE and NSE) under Regulation 39(3) of SEBI (Listing Obligation and Disclosure Requirements), 2015. It informs about the issuance of a duplicate share certificate in lieu of a lost share certificate. This is a regulatory compliance communication related to share certificates and does not contain financial data, management discussion, or report content. It is not an announcement of voting results, board changes, or capital changes. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-12-10 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of Lupin Diagnostics business in India. It is addressed to stock exchanges as a disclosure pursuant to SEBI regulations, indicating it is a regulatory announcement. The content focuses on business strategy and operational commencement rather than financial results or detailed financial data. There are no financial statements, earnings data, or management discussion of financial performance. The document is about a business update and is a formal disclosure to the stock exchange. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not announcing the release of a report but rather a business launch. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories. The document length (6678 characters) supports it being a full disclosure rather than a brief notice.
2021-12-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.